| INTRODUCTION
Solid-organ transplantation is a lifesaving procedure for children with end-organ disease and has resulted in dramatically improved survival.
Prolonged survival, however, has uncovered significant morbidity among childhood recipients.
1 Chronic kidney disease (CKD) is a common comorbidity among the nonrenal solid organ transplant population that often progresses to kidney failure, leading to increased mortality. 2 In children, the reported incidence of CKD in heart, lung, and liver recipients ranges from 29% to 38%, depending on the organ transplanted, [3] [4] [5] [6] [7] but these studies used inconsistent definitions with variable follow-up. Reported risk factors for CKD include use of cyclosporine as primary immunosuppression, older age at transplant, pretransplant diabetes, and impaired kidney function prior to transplant. 3, 5, 7, 8 Acute kidney injury (AKI) is common among adult nonkidney solid organ transplant recipients. Rates of AKI range from 52% to 76% after heart, liver, and lung transplants using the Kidney Disease: Improving Global Outcomes (KDIGO) criteria [9] [10] [11] or Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) AKI criteria. 12 In the pediatric population, the incidence of AKI after nonkidney solid organ transplant is relatively unknown.
The definitions used currently for children are the pediatric RIFLE criteria based on percentage decrease in estimated glomerular filtration rate (eGFR), and the Acute Kidney Injury Network and KDIGO criteria both based on percentage increase in serum creatinine from a baseline creatinine value. 13, 14 Understanding the burden of AKI in the pediatric nonkidney solid organ transplant population will enable physicians to better inform families of risk for kidney injury after transplant and associated morbidity and mortality.
Peritransplant kidney function has also been shown to be an important risk factor for chronic kidney dysfunction in the adult nonkidney solid organ transplant population. 9, [15] [16] [17] A recent study of adult liver transplant recipients, however, found that the decline in kidney function over the first year posttransplant was more strongly associated with posttransplant mortality than GFR at the time of transplant. 18 Understanding when AKI occurs and how it may impact future kidney function is of paramount importance in the solid organ transplant population as it can aid in identifying those at risk for chronic kidney dysfunction and allow for earlier implementation of kidney-sparing strategies to halt or slow progression to kidney failure. The relationship between posttransplant AKI with CKD and mortality has not been investigated in children. This study determined the incidence rate of acute and chronic kidney injury and examines their relationship among childhood recipients of nonkidney solid organ (heart, lung, liver, and multiorgan) transplants.
| METHODS AND MATERIALS

| Study design and population
All first-time recipients <18 years old who received a nonkidney solid organ transplant, including heart, lung, liver, and multiorgan transplant (any combination of bowel, liver, stomach, and pancreas) at the 
| Definitions
| Acute kidney injury
Baseline creatinine was defined as the lowest serum creatinine value within 3 months prior to the serum creatinine used to diagnose AKI.
AKI was defined as an increase in serum creatinine >26.5 μM (0.3 mg/ dL) within 48 hours or an increase in serum creatinine >1.5 times the baseline creatinine value within the previous 7 days based on the KDIGO criteria. 21 AKI events in the first week posttransplant were defined as perioperative AKI events. There was also a minimum 7-day period between AKI events, based on the Acute Kidney Disease Quality Initiative consensus for acute kidney disease. 22 Data to examine urine output criteria were not available. The number of repeated AKI events was determined over the first year posttransplant. A figure illustrating multiple AKIs events is shown in Figure 1B. 
| Chronic kidney disease and end-stage renal disease
CKD was defined as an average eGFR <60 mL/min per 1.73 m 2 over any 6-month period starting at day 90 posttransplant and events were then validated through chart review ( Figure 1C ). The 6-month period was used instead of the standard 3-month period to be more conservative in defining CKD, as many children had long AKI episodes that would meet criteria for CKD but recovered shortly afterward. Endstage renal disease (ESRD) was defined as initiation of renal replacement therapy (either dialysis or a kidney transplant), or an average eGFR <15 mL/min per 1.73 m 2 for any 3-month period ( Figure 1D ).
| Statistical analysis
Baseline characteristics were examined by organ group using means and standard deviations for normally distributed data or medians and interquartile ranges (IQRs) for skewed data. Incidence rates of CKD were calculated per 1000 person-years with 95% confidence intervals (CIs). Cumulative incidence of CKD/ESRD was compared across all organ groups using Kaplan-Meier analysis.
The relationship between AKI in the first year and the develop- and retransplant. 24 Children with AKI events prior to their CKD were manually checked to ensure AKIs were resolved prior to and therefore separate from the CKD event. The eGFR at time of transplant, age, and sex were included as potential confounders, determined a priori, and also confirmed with differences by AKI status. There was considerable overlap of persons with perioperative AKI and AKI, and thus the 2 were analyzed in separate regression models.
The association of AKI as a binary variable (yes, no) with mortality was examined at the same landmarks accounting for competing risk of retransplant. Similarly, the relationship between CKD/ESRD and patient mortality was also examined. Both mortality analyses were adjusted for age, sex, baseline GFR, and underlying diagnosis.
Slope of eGFR over time was estimated using linear regression.
The slopes of eGFR from 3 to 6 months and 3 to 12 months posttransplant were compared for those with no AKI events vs those with 1 or more AKI events within 3 months of transplant using t tests. The risk of developing CKD by AKI severity (Stages 1, 2, and 3) 21 was assessed using a competing risk model. The risk of developing CKD by average tacrolimus level was also assessed using a competing risk model. A Bland-Altman plot was used to assess agreement between estimated and nuclear GFRs measured on the same day for 223 individuals.
Statistical analysis was performed with STATA 14 and a 2-sided P < .05 was considered statistically significant.
| RESULTS
| Baseline characteristics
A total of 303 pediatric nonkidney solid organ transplant recipients were included in the study ( Table 1 ). The majority of the cohort was made up of liver (48%) and heart (41%) recipients. The median age at transplant was 4 years (IQR: 1-12) but lung recipients were notably older at transplant with a median age of 13 years. The main diagnoses for end organ failure were congenital heart disease (42%) and cardiomyopathy (58%) for heart recipients, biliary atresia (35%) and acute liver failure (23%) for liver recipients, and cystic fibrosis (63%) and primary pulmonary hypertension (13%) for lung recipients. The . Tacrolimus-based immunosuppression was used after transplant in 78% of children and 5%
transitioned from cyclosporine to tacrolimus within the first 90 days posttransplant (Table S1) . A kidney-sparing protocol of sirolimus with either a low dose of tacrolimus or no calcineurin inhibitor was used in 9% of children.
| Incidence of AKI, CKD, and ESRD
Children were followed exclusively at the Hospital for Sick Children 
| Relationship between AKI and CKD
Perioperative AKI had a high incidence among our population and was not associated with CKD even after adjusting for age, sex, and The slope of eGFR in the first year after transplantation did not significantly differ among those who had an AKI event in the first 3 months vs those who did not (Table S2 ). Neither severity of first AKI nor average tacrolimus level was associated with increased risk of CKD development (Tables S3 and S4 ). eGFR and nuclear GFR measurements also had good agreement with a mean difference of −3.89 mL/min per m 2 (95% limits of agreement −59.31, 51.53; Figure S2A ). Overall, as GFR increases, the difference between measured and estimated GFR becomes larger, which is expected based on how the eGFR equation was developed ( Figure S2B ). 19 Appropriately for our study purposes, there is more accuracy evident for measures with lower GFRs (60 mL/ min per m 2 and under), which are used to classify CKD and ESRD events.
| Relationship between kidney injury and mortality
Overall, there were 31 deaths and 13 retransplants in the competing risk analysis. There was no significant difference in risk of mortality for those with 1 or more AKI events compared to those with no events (Table 4) . Children who developed CKD or ESRD had high risk of mortality at 6 and 12 months posttransplant, and this association remained significant after adjusting for age, sex, eGFR at transplant, and underlying diagnosis (6 month HR: 30.9, 95% CI, 4.59-208; 12-month HR: 10.8, 95% CI, 3.07-38.3).
| DISCUSSION
Kidney disease impacts survival of children after solid organ transplantation. We were able to identify discrete patterns of kidney injury among recipients of pediatric nonkidney solid-organ transplants. Over two thirds of pediatric heart, lung, liver, and multiorgan transplant recipients have at least 1 AKI event in the first week after transplant and about one third have at least 1 AKI event after the first week and up to 1 year after transplantation, with the highest incidence among Model was adjusted for age, sex, glomerular filtration rate at time of transplant, and underlying diagnosis. AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; ESRD, end-stage kidney disease; HR, hazard ratio.
T A B L E 4 Association of AKI or CKD/ ESRD with risk of mortality accounting for competing risk of retransplant among 303 pediatric nonkidney transplant recipients multiorgan recipients. The overall incidence of CKD/ESRD is 9%, with lung and multiorgan recipients having the highest rates. Over a median follow-up of 3.4 years, AKI events in the first 3 months (excluding those in the first week) were associated with greater than a 2.5-fold higher risk of CKD, with a significant trend over increasing number of AKI events. Those who developed ESRD in the cohort developed it within a range of 14-65 days after transplantation. Also, developing AKI and subsequent CKD increased the risk of mortality significantly.
Due to adverse impact on morbidity and mortality associated with kidney disease, this study provides a rationale to screen early for kidney disease after transplantation and implement strategies to prevent chronic kidney injury.
In our study, lung and multiorgan recipients had the highest rates of AKI and CKD/ESRD. This finding is consistent with prior reports where intestine and lung recipients had the highest incidence of ESRD, followed by heart and liver recipients. 25 In our population, the older age of lung recipients at time of transplant may have contributed to the higher incidence of CKD, as older age has been previously associated with higher risk of CKD/ESRD. 3, 8 Additionally, the lung recipients were more likely to receive cyclosporine-based immunosuppression, which may also contribute to the higher incidence among this group. As well, cystic fibrosis is the most common reason for lung transplant in this cohort, which has been linked to limited functional kidney reserve due to chronicity of disease and use of aminoglycosides, and can often complicate assessment of kidney function from lower muscle mass and poorer nutritional state. 26 Multiorgan recipients in this study received mainly intestine transplants with a liver or other visceral organ. Factors contributing to kidney injury in this group include the higher levels of immunosuppression in intestinal transplantation due to the high immunogenicity of the bowel, pretransplant diagnoses of congenital anomalies typically seen in preterm infants that increase risk for kidney dysfunction, as well as hypovolemia in the peritransplant period related to poor fluid absorption. 25 Both lung and multiorgan recipients are at higher risk for CKD and may require minimization of nephrotoxic drugs or other agents such as radiocontrast early after transplant to slow kidney disease progression.
We also report that AKI episodes over the first 3 months are associated with the development of CKD. Other studies investigating AKI and long-term kidney dysfunction in adult transplant recipients have reported a similar association. However, these studies defined AKI within the first 3 to 7 days after transplant and were unable to examine the incidence of AKI over a year or analyze repeated AKI events. 9, 11 As shown recently, kidney function in the first year after a liver transplant may in fact be a more important indicator for long-term kidney function than in the perioperative period of the transplant. 18 In our cohort, we found that having even 1 AKI episode within the first 3 months places children at greater risk for CKD after adjusting for eGFR at time In this study, we found that in the first week posttransplant there were many fluctuations in creatinine possibly due to volume status, which is a significant issue in young children. 28 This study has a number of strengths. It is the first study to report incidence of AKI among the pediatric nonkidney solid organ transplant population and examines AKI events over time in addition to the perioperative period to better describe the incidence of AKI and its association with CKD. It also has a large sample size for a pediatric transplant cohort, includes multiple organ groups, and comes from a population with universal access to health care and lifelong coverage of medications.
The study also has some limitations. We could not assess whether each episode of AKI was associated with a specific cause for each event such as rejection or infection, which would need to be studied prospectively. The study also used the modified Schwartz formula, which has been known to overestimate low GFR values, is not validated among children under age 2 years, and requires height information, which was not available for all creatinine measurements. Nevertheless, we were able to estimate height using closest height measurement z-scores and correlate the eGFR to nuclear GFR measurements taken on the same day (456 measurements from 223 children) to ensure the eGFR did not significantly deviate from nuclear GFR. In very young children under age 2 years, 96% of eGFR measurements were within the limits of agreement. As well, we could not account for AKI events after the first year because children who were doing well did not come frequently for routine monitoring and had fewer measures of serum creatinine after that time. Finally, as this study took place over time with varying calcineurin inhibitor protocols, it was difficult to examine the risk of AKI and CKD due to cumulative drug exposures, which is an area to explore in the future. We assessed average tacrolimus levels in the first 3 months after transplant as 1 measurement; however, further analysis should take into account time-varying levels. We adjusted for potential confounders; however, due to the limited sample size, residual confounding remains an issue and larger studies are needed to confirm the findings.
AKI and CKD are common in children with nonkidney solid organ transplants, especially among lung and multiorgan recipients.
Perioperative AKI is common but not associated with development of CKD. AKI after the first week and up to 3 months posttransplant is significantly associated with 2.5 times greater risk of developing CKD.
After a nonkidney solid organ transplant, children should be monitored closely for changes in kidney function to better identify those at risk for CKD and allow for earlier implementation of kidney-sparing strategies to prevent kidney disease progression.
